To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in ...

report Teva’s Copaxone marketing tactics have caused trouble for the drugmaker beyond Europe as well. Earlier this month, Teva Pharmaceuticals USA and Teva Neuroscience agreed to pay a combined ...

The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on ...

“Teva (TEVA) conducts its business lawfully and ethically and has been a strong partner to Europe, its patients, economy and healthcare systems,” the company added.

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceutical, the world’s largest generic drugmaker, was fined $503 million by European antitrust regulators for delaying competition to a blockbuster multiple sclerosis medicine.

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...

Teva Pharmaceutical Industries TEVA reported third-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...

To do that, Teva conducted a “disparagement campaign” against Synthon, the only other company with an authorized drug in Europe containing glatiramer acetate, the commission said in a statement.